SANBIO COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 506 JPY | +1.20% |
|
+8.12% | -27.92% |
| Mar. 19 | SanBio Eyes Approval for Brain Injury Treatment Drug SB623 By March | MT |
| Mar. 19 | Jefferies Adjusts SanBio’s Price Target to 270 Yen From 310 Yen, Keeps at Underperform | MT |
| Sales 2025 * | - | Sales 2026 * | 660M 4.19M | Capitalization | 34.73B 221M |
|---|---|---|---|---|---|
| Net income 2025 * | -3.3B -20.93M | Net income 2026 * | -3.53B -22.41M | EV / Sales 2025 * | - |
| Net Debt 2025 * | 226M 1.44M | Net Debt 2026 * | 3.03B 19.28M | EV / Sales 2026 * | 57.2 x |
| P/E ratio 2025 * |
-10.3
x | P/E ratio 2026 * |
-9.66
x | Employees | 29 |
| Yield 2025 * |
-
| Yield 2026 * |
-
| Free-Float | 71.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on SanBio Company Limited
More recommendations
More press releases
| 1 day | +1.20% | ||
| 1 week | +8.12% | ||
| 1 month | +21.93% | ||
| 3 months | -37.06% | ||
| 6 months | -1.56% | ||
| Current year | -27.92% |
1 week
470.00
520.00
1 month
417.00520.00
Current year
380.00910.00
1 year
380.00910.00
3 years
380.002 220.00
5 years
380.004 620.00
10 years
380.0012 730.00
| Managers | Title | Age | Since |
|---|---|---|---|
Keita Mori
CEO | Chief Executive Officer | 57 | 13-02-26 |
Shinya Hirata
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Noboru Kotani
BRD | Director/Board Member | 67 | 13-02-28 |
Keita Mori
CEO | Chief Executive Officer | 57 | 13-02-26 |
Toru Kawanishi
CHM | Chairman | 56 | 13-02-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 2 M€ | -.--% | ||
| 0.01% | 7 M€ | -.--% | - | |
| 0.00% | 32 M€ | +0.28% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 746 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 506 | +1.20% | 2,176,700 |
| 24-05-30 | 500 | +0.20% | 459,900 |
| 24-05-29 | 499 | +0.81% | 767,200 |
| 24-05-28 | 495 | +3.99% | 1,376,100 |
| 24-05-27 | 476 | +1.71% | 552,600 |
Delayed Quote Japan Exchange, May 31, 2024 at 02:00 am EDT
More quotes
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).
Calendar
2024-06-12
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
506
JPY
Average target price
800
JPY
Spread / Average Target
+58.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.92% | 221M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- 4592 Stock
